The invalidation removes one patent from the ongoing Halozyme-Merck litigation, but many related patents remain in dispute. Monitor the remaining PGRs and the district court case for further developments.
MRK drugs
MRK drug pipeline →- ● ENFLONSIA 4/10 Approved · PDUFA date Mar 22, 2027
- ● IDVYNSO 4/10 Approved · PDUFA date Apr 22, 2027
- ▲ sac-TMT 6/10 Filed/PDUFA (Phase 3 data complete; BLA under priority review) · PDUFA date Jun 15, 2027
- ● GARDASIL 4/10 Approved
- ● LAGEVRIO 4/10 EUA (Emergency Use Authorization) / Marketed
- 15 more · All MRK drugs, catalysts & trials →
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 10 $148.05entry
- T+1 · 6d ago −0.59%α −1.91% · $147.18
- T+4 · todayOpen
- T+5 · in 7h Pending
- T+20 · in 22d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outExecutive Summary
In a final written decision, the PTAB held all challenged claims (1, 2, 5, and 7–33) of Halozyme's PH20 hyaluronidase patent unpatentable on written description, enablement, and obviousness grounds. Merck Sharp & Dohme LLC, the petitioner, succeeded in invalidating the patent, which is part of a broader patent dispute between Halozyme and Merck.
PTAB Trial Details
Key Facts
- PTAB issued a final written decision in PGR2025-00042, finding claims 1, 2, 5, and 7–33 of U.S. Patent 12,037,618 unpatentable.
- The patent covers modified PH20 hyaluronidase polypeptides with increased stability and/or activity.
- Merck Sharp & Dohme LLC (a subsidiary of Merck & Co.) was the petitioner; Halozyme, Inc. was the patent owner.
- The decision is based on lack of written description, lack of enablement, and obviousness over the '429 patent and Chao prior art.
- The '618 patent is one of many patents in a related district court action (Halozyme v. Merck, 2:25-cv-03179 D.N.J.) and multiple other PGRs and IPRs.
Financial Impact
Not stated in the decision; no financial figures provided.
Risk Factors
- The decision may be appealed to the Federal Circuit; the patent could be reinstated.
- Other related patents in the same family are still being challenged in separate PTAB proceedings and the district court.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 PTAB decision.
| Document | Accession Number |
|---|---|
| PTAB-TRIAL Data (Synthetic) | ptab-PGR2025-00042-fwd-MRK |
Track record
34 reports on MRK
3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +16.92% at T+20 after the Aug 6, 2026 report. 6 of 7 went positive at some point.
Filters
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $147.76 Now $144.46 −2.23% settles Feb 11
- Nov 9, 20268d ago PTAB Trial Neutral 2/10 Viewing Entry $148.05 Now $144.46 −2.42% settles Feb 8
- Nov 3, 202613d ago 3 Neutral 2/10 Entry $144.67 Now $144.46 −0.15% settles Feb 1
- Nov 3, 202613d ago Institutional Cluster Bearish 4/10 Entry $144.67 Now $144.46 +0.15% settles Feb 1
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $144.67 Now $144.46 −0.15% settles Feb 1
- Oct 29, 202618d ago 8-K Neutral 5/10 Entry $146.33 Now $144.46 −1.28% settles Jan 27
- Oct 22, 202625d ago 3/A Neutral 1/10 Entry $145.27 Now $144.46 −0.56% settles Jan 21
- Oct 21, 202627d ago PTAB Trial Neutral 3/10 Entry $147.24 Now $144.46 −1.89% settles Jan 20
- Oct 15, 20264w ago PTAB Trial Bullish 6/10 Entry $145.95 Now $144.46 −1.02% settles Jan 13
- Oct 15, 20264w ago PTAB Trial Bullish 5/10 Entry $145.95 Now $144.46 −1.02% settles Jan 13
US Market Status
Subscribe to SecBot
Get Real-Time PTAB Decision Intelligence
Market-moving PTAB patent decisions analyzed within minutes. Trial institutions, denials, final written decisions, and more, parsed and scored by AI.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers